‣ Xtandi with IO combo- please refer chapter no . 7
5 . Zytiga + ARN-509- How big is it has potential to change the treatment paradigm of Prostate Cancer ? A competitive threat post Zytiga patent expiry for Xtandi ?
‣ Zytiga generic entry : An opportunity for ARN-509 or A threat for JNJ ?
‣ Zytiga patent Expiry- more worries for early entry in US market than Ex-US
‣ Use patents of Zytiga : the 438 Patent
‣ Ongoing clinical trial of Zytiga with ARN-509
‣ Ongoing clinical trials of Zytiga with Xtandi
‣ New formulation under development for Zytiga / Xtandi
‣ Combination studies of Zytiga with other targeted therapy vs . combination study of Xtandi with other targeted therapies , Ongoing Clinical trials
‣ Combination of Zytiga with Onapristone
Browse All Reports of This Category at : https :// marketreportscenter . com / reports / category / life-sciences
6 . Pipeline Antiandrogens : Androgen Receptor Inhibitors vs . Androgen Synthesis inhibitors-
‣ Androgen Receptor inhibitors : Who could be the major threat to Xtandi ?
� ARN-509- A better Xtandi is in making o Ongoing Clinical trials of ARN-509 and our expectations o ARN-509- Clinical data comparison vs . Xtandi and other pipeline candidates � ODM-201- Does its safety differentiate it against ARN-509 / Xtandi ? �
�
ODM-201 and ODM-204 has potential to challenge current leader Xtandi and Zytiga
EPI-001 and EPI-506